More recently intravenous immunoglobulin IVIG has been in short supply. Reason for the Shortage.
Intravenous Immunoglobulin Immunotherapy For Coronavirus Disease 19 Covid 19 Galeotti 2020 Clinical Amp Translational Immunology Wiley Online Library
5 6 The coronavirus disease 2019 COVID19 pandemic has introduced additional stress on the plasma supply.
Ivig shortage 2020. The pandemics potential impact on the global Ig supply chain highlighted the urgent need to have an Ig shortage management plan in place. April 6 and August 28 2020. This shortage could impact patient care.
ADMA Biologics personal communication. IVIG is an essential therapy for the treatment of many debilitating andor life-threatening immunodeficiency and immune dysregulatory disorders. The purpose of this memorandum is to communicate the Massachusetts Department of Public Healths the Department awareness of ongoing nationwide Intravenous Immune Globulin IVIG shortages.
In the setting of the increased demand for IG other factors that ordinarily might not impact availability may have a greater effect. ADMA Biologics has Bivigam on allocation through BioCare SD1-2 CSL Behring has Hizentra and Privigen on shortage due to increased demand3. In the interview with the Cornell Daily Sun patient advocate Michelle Vogel indicated that some providers have switched IVIG brands in shortage to brands with a larger supply.
July 11 August 26 and September 24 2019. This was later confirmed by Dana Lynch a representative from CSL Behring which manufactures IVIG brands Privigen and Hizentra according to the article. The information contained in the table is generally provided to CBER by the manufacturer of the CBER-regulated product that is in.
In 2019 a significant scarcity of IVIG resulted in local shortages and rationing. A table identifying current shortages of CBER-regulated products. The Food and Drug Administration FDA confirms that the demand for IVIG products has increased over recent years and along with production and distribution issues an ongoing shortage of IVIG products across the United States will exist through April 2020.
NAC had initiated planning to develop a national Ig shortage plan but had not yet started the work when the COVID-19 pandemic struck in early 2020. The current shortage of immune globulin for intravenous use IVIG is being attributed to several events including an increase in off-label use and intense Food and Drug Administration FDA scrutiny of product lots and manufacturing facility upgrades that result in temporary production halts1 Additionally there has been an increase in product recall or failure to release product because. Drug shortages statistics and best practices guidelines and publications related to drug shortages.
